[{"id":"79ff0d7f-8e12-46e7-a59f-373c976c10bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05638542","created_at":"2022-12-06T15:57:57.071Z","updated_at":"2024-07-02T16:35:50.646Z","phase":"","brief_title":"Comparison of Expression of Carcinogenesis-related Molecular Markers in the Patients With Colon Cancer and Polyp","source_id_and_acronym":"NCT05638542","lead_sponsor":"Seoul National University Bundang Hospital","biomarkers":" EGFR • PD-L1 • KRAS • BRAF • TP53 • MSI • MLH1 • MSH6 • MSH2 • PMS2 • RUNX3 • IL1B • NLRP3 • NEUROG1 • CASP1","pipe":" | ","alterations":" PD-L1 expression • TP53 mutation • KRAS mutation • EGFR mutation • MSI-H/dMMR • BRAF mutation • EGFR expression • PMS2 mutation • TP53 expression • PD-L1 mutation","tags":["EGFR • PD-L1 • KRAS • BRAF • TP53 • MSI • MLH1 • MSH6 • MSH2 • PMS2 • RUNX3 • IL1B • NLRP3 • NEUROG1 • CASP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • TP53 mutation • KRAS mutation • EGFR mutation • MSI-H/dMMR • BRAF mutation • EGFR expression • PMS2 mutation • TP53 expression • PD-L1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 582","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 01/30/2021","primary_completion_date":" 01/30/2021","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-04-13"},{"id":"25b49b5c-1205-49a0-873e-9be6de80eb2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03576963","created_at":"2021-01-18T14:26:35.700Z","updated_at":"2025-02-25T14:27:13.292Z","phase":"Phase 1/2","brief_title":"Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03576963","lead_sponsor":"University of Southern California","biomarkers":" PD-L1 • IGF2 • SOCS1 • RUNX3 • NEUROG1","pipe":" | ","alterations":" RAS wild-type","tags":["PD-L1 • IGF2 • SOCS1 • RUNX3 • NEUROG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • guadecitabine (SGI-110)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/30/2020","start_date":" 01/30/2020","primary_txt":" Primary completion: 01/30/2022","primary_completion_date":" 01/30/2022","study_txt":" Completion: 01/30/2023","study_completion_date":" 01/30/2023","last_update_posted":"2021-04-05"}]